# A Study of SHR-A1811 Combined With Capecitabine in Treatment of Unresectable or Metastatic Breast Cancer With Low HER2 Expression.

> **NCT05845138** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Suzhou Suncadia Biopharmaceuticals Co., Ltd.** · enrollment: 116 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** SHR-A1811 for injection ; capecitabine

## Key facts

- **NCT ID:** NCT05845138
- **Lead sponsor:** Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-07-25
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 116 (ESTIMATED)
- **Last updated:** 2023-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05845138

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05845138, "A Study of SHR-A1811 Combined With Capecitabine in Treatment of Unresectable or Metastatic Breast Cancer With Low HER2 Expression.". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05845138. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*